DDInter1802 DDInter1628
Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Ticagrelor {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Ticagrelor {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anagrelide
Anagrelide {u} (Compound) upregulates {v} (Gene) CPSF4
CPSF4 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anagrelide
Anagrelide {u} (Compound) downregulates {v} (Gene) PSMG1
PSMG1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Vinorelbine {u} (Compound) upregulates {v} (Gene) IRAK1
IRAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Bexarotene {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Ticagrelor (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Ticagrelor (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ruxolitinib (Compound)
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide (Compound) upregulates CPSF4 (Gene) and CPSF4 (Gene) is downregulated by Ruxolitinib (Compound)
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide (Compound) downregulates PSMG1 (Gene) and PSMG1 (Gene) is downregulated by Ruxolitinib (Compound)
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Ruxolitinib (Compound)
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine (Compound) upregulates IRAK1 (Gene) and IRAK1 (Gene) is bound by Ruxolitinib (Compound)
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)